Inovio (NASDAQ: INO) director receives RSUs and stock options grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

INOVIO PHARMACEUTICALS, INC. director Lota S. Zoth received new equity awards as part of non-employee director compensation. She was granted 34,200 restricted stock units, each representing one future share of common stock, and 41,800 stock options with a $1.23 exercise price.

Both the RSUs and options were granted under the company’s 2023 Omnibus Incentive Plan and are scheduled to vest 100% on May 20, 2027. These are compensation-related grants rather than open-market share purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Zoth Lota S.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Options	41,800	$0.00	--
Grant/Award	Restricted Stock Unit	34,200	$0.00	--

Holdings After Transaction: Common Stock Options — 41,800 shares (Direct, null); Restricted Stock Unit — 34,200 shares (Direct, null)

Footnotes (1)

This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. Options to vest 100% on May 20, 2027. Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.

Key Figures

Restricted stock units granted: 34,200 units Stock options granted: 41,800 options Option exercise price: $1.23 per share +5 more

8 metrics

Restricted stock units granted 34,200 units Grant to director Lota S. Zoth on May 20, 2026

Stock options granted 41,800 options Grant to director Lota S. Zoth on May 20, 2026

Option exercise price $1.23 per share Exercise price for 41,800 Common Stock options

RSU vesting date May 20, 2027 100% of 34,200 RSUs vest on this date

Option vesting date May 20, 2027 100% of 41,800 options vest on this date

Option expiration date May 20, 2036 Expiration for 41,800 Common Stock options

RSUs following transaction 34,200 units Total RSUs held after the grant

Options following transaction 41,800 options Total options held after the grant

Key Terms

Restricted Stock Unit, 2023 Omnibus Incentive Plan, non-employee director compensation policy, Common Stock Options, +1 more

5 terms

Restricted Stock Unit financial

"security_title: Restricted Stock Unit; each represents a contingent right to one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

2023 Omnibus Incentive Plan financial

"This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's policy"

non-employee director compensation policy financial

"made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy"

Common Stock Options financial

"security_title: Common Stock Options with an exercise price of 1.2300"

vest 100% on May 20, 2027 financial

"Options to vest 100% on May 20, 2027 and RSUs will vest 100% then"

Form 4 Insider Transactions: What Each Field Means →

05/21/2026 - 04:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zoth Lota S.

(Last)

(First)

(Middle)

660 W. GERMANTOWN PIKE

SUITE 110

(Street)

PLYMOUTH MEETING

PENNSYLVANIA

19462

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INOVIO PHARMACEUTICALS, INC. [ INO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock Options	$1.23	05/20/2026		A		41,800⁽¹⁾		⁽²⁾	05/20/2036	Common Stock	41,800	$0	41,800	D
Restricted Stock Unit	⁽³⁾	05/20/2026		A		34,200⁽¹⁾		⁽³⁾	⁽³⁾	Common Stock	34,200	$0	34,200	D

Explanation of Responses:

1. This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.

2. Options to vest 100% on May 20, 2027.

3. Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.

Remarks:

	/s/ Lota Zoth	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Inovio (INO) director Lota S. Zoth receive?

Lota S. Zoth received 34,200 restricted stock units and 41,800 stock options. Each RSU equals one common share, and the options are exercisable at $1.23 per share as part of her director compensation.

What is the exercise price and term of Lota S. Zoth’s Inovio stock options?

Her Inovio stock options cover 41,800 underlying shares at an exercise price of $1.23 per share. The options were granted on May 20, 2026 and are scheduled to expire on May 20, 2036, if not exercised earlier.

When do Lota S. Zoth’s Inovio RSUs and options vest?

Both the 34,200 restricted stock units and the 41,800 stock options for Lota S. Zoth vest 100% on May 20, 2027. Vesting must occur before RSUs settle into shares or options become fully exercisable.

Under what plan were the new Inovio (INO) director awards granted?

The RSUs and stock options granted to director Lota S. Zoth were issued under Inovio’s 2023 Omnibus Incentive Plan. The awards were made pursuant to the company’s non-employee director compensation policy outlined in that plan.

Does this Inovio Form 4 show any open-market stock purchases or sales?

No, the Form 4 shows only compensation-related equity grants to director Lota S. Zoth. It reports awards of restricted stock units and stock options, without any open-market purchases or sales of Inovio common stock.